07.15.15
Intellijoint Surgical Inc., a privately held Canadian medical technology company, launched its flagship product—Intellijoint Hip—in Canada.
The device also has U.S. Food and Drug Administration clearance and hit the U.S. market in March.
According to the company, the Intellijoint Hip is an instrument that provides surgeons with “vital intraoperative measurements enabling proper cup position, equalization of leg length and restoration of hip offset.”
These critical measurements can assist in the prevention of recurrent instability, hip dislocation and leg length discrepancy. Intellijoint Hip benefits from the company’s proprietary core technology, a miniaturized surgical grade tracking system placed in the sterile field.
“Intellijoint Hip is a revolutionary smart tool that will make a significant impact on patient outcomes in hip replacement surgery and health care system costs worldwide,” said Armen Bakirtzian, co-founder and CEO of Intellijoint Surgical. “Use of our device will reduce costly readmissions and unnecessary revision surgeries while improving clinical outcomes and patient satisfaction. We are extremely excited for this milestone and the next steps in our company’s growth.”
The company has successfully conducted a limited launch of Intellijoint Hip with more than 200 live surgeries in the United States and Canada. The commercial launch will commence in Ontario, and expand to the rest of the country.
“The number of hip replacements performed around the world continues to grow at a very high rate,” said Allan Gross, M.D., orthopedic surgeon at Mount Sinai Hospital in Toronto, and chairman of Intellijoint’s Scientific Advisory Board. “Intellijoint Hip gives surgeons a fast, accurate, and cost-effective tool to enhance patient outcomes and prevent costly mistakes.”
Based in Waterloo, Ontario, Intellijoint Surgical was founded in 2010. Focusing first on hip surgery, the company develops and commercializes miniaturized smart tools that enhance surgeon accuracy, increase hospital economic efficiencies, and improve patient outcomes. The company’s R&D team is led by the former co-founder of computer assisted surgery at Medtronic plc, and driven by a team of renowned orthopedic surgeons in the United States and Canada.
The device also has U.S. Food and Drug Administration clearance and hit the U.S. market in March.
According to the company, the Intellijoint Hip is an instrument that provides surgeons with “vital intraoperative measurements enabling proper cup position, equalization of leg length and restoration of hip offset.”
These critical measurements can assist in the prevention of recurrent instability, hip dislocation and leg length discrepancy. Intellijoint Hip benefits from the company’s proprietary core technology, a miniaturized surgical grade tracking system placed in the sterile field.
“Intellijoint Hip is a revolutionary smart tool that will make a significant impact on patient outcomes in hip replacement surgery and health care system costs worldwide,” said Armen Bakirtzian, co-founder and CEO of Intellijoint Surgical. “Use of our device will reduce costly readmissions and unnecessary revision surgeries while improving clinical outcomes and patient satisfaction. We are extremely excited for this milestone and the next steps in our company’s growth.”
The company has successfully conducted a limited launch of Intellijoint Hip with more than 200 live surgeries in the United States and Canada. The commercial launch will commence in Ontario, and expand to the rest of the country.
“The number of hip replacements performed around the world continues to grow at a very high rate,” said Allan Gross, M.D., orthopedic surgeon at Mount Sinai Hospital in Toronto, and chairman of Intellijoint’s Scientific Advisory Board. “Intellijoint Hip gives surgeons a fast, accurate, and cost-effective tool to enhance patient outcomes and prevent costly mistakes.”
Based in Waterloo, Ontario, Intellijoint Surgical was founded in 2010. Focusing first on hip surgery, the company develops and commercializes miniaturized smart tools that enhance surgeon accuracy, increase hospital economic efficiencies, and improve patient outcomes. The company’s R&D team is led by the former co-founder of computer assisted surgery at Medtronic plc, and driven by a team of renowned orthopedic surgeons in the United States and Canada.
